A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors
Latest Information Update: 10 Feb 2023
Price :
$35 *
At a glance
- Drugs KD 496 (Primary)
- Indications Gastric cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 21 Oct 2022 New trial record